塞来昔布对比安慰剂辅助治疗乳腺癌无病生存的REACT随机临床试验
REACT研究为3期随机双盲试验,纳入2639例ERBB2阴性完全切除的乳腺癌患者,按2:1随机接受塞来昔布400mg每日一次或安慰剂治疗2年。中位随访74.3个月,两组无病生存事件率分别为18%与19%,5年无病生存率84%与83%,风险比0.97(95%CI 0.80-1.17;
要点
- 塞来昔布辅助治疗2年未改善ERBB2阴性乳腺癌无病生存。
- 两组毒性反应均较低,未见差异。
核心结论
- 在ERBB2阴性乳腺癌辅助治疗中,与安慰剂相比,塞来昔布治疗2年未显示无病生存获益。
研究设计与样本
- REACT为3期随机双盲试验,在英国和德国160个中心开展,2007年1月19日至2012年11月1日招募2639例完全切除的ERBB2阴性乳腺癌患者,按2:1随机接受塞来昔布或安慰剂。
主要发现
- 中位随访74.3个月(四分位距61.4-93.6个月),487例(19%)报告无病生存事件,塞来昔布组18%(323/1763,5年无病生存率84%)vs 安慰剂组19%(164/876,5年无病生存率83%)。
- 两组毒性反应率均较低,无差异证据。
关键数值与推荐
- 塞来昔布400mg每日一次口服2年;主要终点为意向治疗人群的无病生存。
临床怎么用
- 不推荐对ERBB2阴性乳腺癌患者常规使用塞来昔布2年辅助治疗以改善无病生存。
- 更长疗程或更高剂量塞来昔布是否带来无病生存获益需进一步研究验证。
局限性
- 原文未报告具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. OBJECTIVE: To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The Randomized European Celecoxib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing 2 years of adjuvant celecoxib vs placebo among 2639 patients recruited between January 19, 2007, and November 1, 2012, with follow-up 10 years after treatment completion. Eligible patients had completely resected breast cancer with local and systemic therapy according to local practice. Patients with ERBB2-positive or node-negative and T1, grade 1 tumors were not eligible. Randomization was in a 2:1 ratio between celecoxib or placebo. Statistical analysis was performed from May 5, 2019, to March 5, 2020. INTERVENTIONS: Patients received celecoxib, 400 mg, or placebo once daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population using Cox proportional hazards regression and log-rank analysis. Follow-up is complete. RESULTS: A total of 2639 patients (median age, 55.2 years [range, 26.8-86.0 years]) were recruited; 1763 received celecoxib, and 876 received placebo. Most patients' tumors (1930 [73%]) were estrogen receptor positive or progesterone receptor positive and ERBB2 negative. A total of 1265 patients (48%) had node-positive disease, and 1111 (42%) had grade 3 tumors. At a median follow-up of 74.3 months (interquartile range, 61.4-93.6 years), DFS events had been reported for 487 patients (19%): 18% for those who received celecoxib (n = 323; 5-year DFS rate = 84%) vs 19% for those who received placebo (n = 164; 5-year DFS rate = 83%); the unadjusted hazard ratio was 0.97 (95% CI, 0.80-1.17; log-rank P = .75). Rates of toxic effects were low across both treatment groups, with no evidence of a difference. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, patients showed no evidence of a DFS benefit for 2 years' treatment with celecoxib compared with placebo as adjuvant treatment of ERBB2-negative breast cancer. Longer-term treatment or use of a higher dose of celecoxib may lead to a DFS benefit, but further studies would be required to test this possibility. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02429427 and isrctn.org Identifier: ISRCTN48254013.
引用
- Coombes RC, Tovey H, Kilburn L, et al. Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34264305. doi:10.1001/jamaoncol.2021.2193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。